Sigma Aldrich), a PPARγ inhibitor, was intravenously administered 1 hour before LAD ligation. Echocardiography was performed using a Vevo 2100 ultrasound system at baseline, 1 week, 2 weeks and 3 weeks after reperfusion. Measurement of systolic blood pressure and heart rate by using tail-cuff method were performed at baseline, 6 hours and 24 hours after reperfusion.
Experimental protocol 7:
To examine the impact of the reducing Ly6C high monocytes on 30-mL acetone. The resultant organic solution was poured into 60 mL of an aqueous PVA solution (0.5% or 2% w/v in distilled water) and stirred at 400 rpm, 40 ºC during the operation. The dispersed solution was then centrifuged (20,000 g for 20 minutes) and the sediments were resuspended in distilled water. The process was repeated and the resultant dispersion was freeze-dried. The redispersion of the nanoparticles prepared in the 2% PVA condition was better than those prepared in 0.5% PVA condition after freeze-drying. It was assumed that PVA on the surface of nanoparticle might improve the wettability and redispersibility 7 . Therefore, we selected the 2% PVA concentration in aqueous phase to prepare irbesartan-PLGA nanoparticles in this system (Supplementary Table 4 ).
Physicochemical characteristic of the irbesartan-nanoparticles
In this study, drug concentration in the organic phase and PVA concentration in aqueous phase were examined to control the particle size and drug content of irbesartan-NP. A transmission electron microscope (TEM, Hitachi H7000E, Tokyo, Japan) was used for the morphological examination of irbesartan-NP ( Supplementary Fig. S8A , B). The particle size was analyzed by a dynamic light scattering method (Microtrack UPA150, Nikkiso, Tokyo, Japan) 8 ( Supplementary Fig. S8C ). A sample of nanoparticle suspension in distilled water was used for particle size analysis. The average diameter of nanoparticles was approximately 200 nm in the all experimental condition (Supplementary Table 4 ). The size distribution was also similar between each drug concentration in organic phase ( Supplementary Fig. S8C ).
The particle size of FITC-NP and ICG-NP was analyzed by the same method, the diameter of FITC-NP was 225 nm and ICG-NP was 253 nm, respectively. On the other hand, increasing of the drug concentration in the organic phase led to a gradual increase of drug content in the nanoparticles (Supplementary Table 4 
Distribution of FITC-nanoparticles
The distribution of FITC in the heart and peripheral blood leukocytes was examined. After myocardial IR, animals were sacrificed, and peripheral blood was drawn by means of cardiac The leukocytes were also incubated with appropriate isotype controls (BD Pharmingen, San Diego, CA, USA).
Monocytes/macrophages were identified as CD11b high (CD90/B220/CD49b/NK1.1/Ly6G) low Ly6C high/low , macrophages were identified as CD11b high (CD90/B220/CD49b/NK1.1/Ly6G) low Ly6C low F4/80 high , neutrophils were identified as CD11b high (CD90/B220/CD49b/NK1.1/Ly6G) high , and lymphocytes were identified as CD11b low (CD90/B220/CD49b/NK1.1/Ly6G) high as previously described 9 .
The distribution of FITC in the heart and peripheral blood leukocytes was examined. After myocardial IR, animals were sacrificed, and peripheral blood was drawn by means of cardiac puncture with EDTA (ethylenediaminetetraacetic acid) as an anticoagulant, and red cells were lysed with VersaLyse Lysing Solution (Becton Dickinson Biosciences, San Jose, CA, USA). The distribution of FITC-NP in the peripheral blood leukocytes was analyzed with a FACSCalibur cytometer (Becton Dickinson Biosciences). The heart was harvested and fixed in 10% phosphate-buffered formalin (pH 7.4), and the distribution of FITC-NP was analyzed in 5-µm OCT-embedded sections. Sections of the heart were evaluated by fluorescence microscopy.
Histological and immunohistochemical analyses
Twelve hours after reperfusion, hearts were harvested and fixed overnight in 10% buffered-formalin. After fixation, the tissue was embedded in paraffin. Serial cross-sections (5-µm thick) were used for analysis. The sections were subjected to immunohistology using anti-MCP-1 antibodies (1:200, Santa Cruz Biotechnology). The degree of MCP-1 expression in the AAR 12 hours after reperfusion was evaluated. Digital images of 5 fields in the AAR per heart were stored, and the MCP-1 staining area was assessed using a 20 × objective.
Western blot analysis
Homogenates of IR myocardium were analyzed with immunoblotting. At predetermined time points, ischemic myocardium was isolated and analyzed as previously reported 10 . Briefly, liquid nitrogen and were sliced into sequential 1-mm-thick cross-sections. The sections were incubated with 2% 2,3,5-triphenyltetrazolium chloride (TTC, Sigma Aldrich) for 10 minutes at 37 °C and were photographed with a stereomicroscope (Nikon, HC-2500) 13, 14 .
In vitro drug release kinetics
Irbesartan-NP was dissolved in PBS (10 mM, pH 7.4) (0.1 mg mL -1 ) and loaded to 10 k MWCO Slide-a-lyzer dialysis cassettes (0.1-0.5 mL, Thermo Scientific) and dialyzed against 1000 mL PBS (10 mM, pH 7.4) at 37 °C. At each time point, 50 µL were removed from inside of the cassette for the measurement of remaining irbesartan 15 .
Chemotaxis assay
THP-1, a human monocyte cell line, was obtained from the German Collection of microchemotaxis Boyden chamber (ChemoTx; Neuroprobe), as described previously 16 .
Monocytes that had transmigrated through the micropore were stained with trypan blue. The number of monocytes that migrated in response to MCP-1 was counted.
Measurements of irbesartan concentrations in the plasma and tissues
Irbesartan concentrations in the plasma and tissues were measured at predetermined time points by liquid chromatography coupled to tandem mass spectrometry (LC/MS/MS). Briefly, the high-performance liquid chromatography (HPLC) analysis was performed using the Data are expressed as the mean ± SD (n=3 each)
